Acorda Therapeutics, Inc. (ACOR) reported premarket FY 2015 first quarter earnings results. The New York-based biopharmaceutical company posted earnings of $0.15 per share on revenues of $99.85 million, up 24% from $80.51 million a year ago. Analysts were expecting EPS of $0.15 on revenues of $99.70 million. The company’s net income for the period was a loss of (3.1) million, or ($0.07) per diluted share, from a profit of $0.7 million, or $0.02 per diluted share, a year earlier.
On valuation measures, Acorda Therapeutics Inc. shares, which currently have an average 3-month trading volume of 595K shares, trade at a trailing-12 P/E of 75.40, a forward P/E of 33.34 and a P/E to growth ratio of 1.85. The median Wall Street price target on the name is $42.41 with a high target of $65.00. Currently ticker boasts 4 ‘Buy’ endorsements, compared to 7 ‘Holds’ and no ‘Sell’.
Profitability-wise, ACOR has a t-12 profit and operating margin of 4.40% and 13.22%, respectively.
Liquidity: At March 31, 2015 the $1.35 billion market cap company reported cash, cash equivalents and investments of $299.70 million. The company said it expects to be cash flow positive in FY/15.
ACOR currently prints a one year loss of about 10% and a year-to-date loss of 22.51%.
The chart below shows where the equity has traded over the last 52 weeks.
Taser International Inc. (TASR) reported first quarter EPS of $0.13 before the opening bell Thursday, compared to the consensus estimate of $0.06. Revenues increased 23.8% from last year to $44.8 million. Analysts expected revenues of $39.97 million. Q1 gross margin in the period was 66.7%, compared to 61.4% in the same period last year.
Meantime, net sales were $44.8 million, an increase of $8.6 million, or 23.7%, compared to first quarter 2014 net sales of $36.2 million.
TASER International is off to an outstanding start in fiscal 2015 thanks to strength in the TASER Weapons segment, as well as continued growth and new wins in the AXON business,” said in a statement Rick Smith, TASER chief executive officer. “New programs such as the Standard Issue Grant Program are examples of how we are partnering with law enforcement agencies for the long-term, and we are enthusiastic thus far about the results of our investments.”
Profitability-wise, TASR has a t-12 profit and operating margin of 12.11% and 19.76%, respectively. The $1.50 billion market cap company reported $104.8 million in cash at March 31, 2015, up from $90.4 million at December 31, 2014.
TASR currently prints a one year return of 64.34% and a year-to-date return of around 6.00%.
The stock is currently up 7.70% to $30.16 on 18K shares.
Radian Group Inc. (RDN) released its earnings results on Thursday. The mortgage insurer reported Q1’15 non-GAAP EPS of $0.35 per share vs. $0.32 consensus on $290.66 million in revenue, up 13% from $258.2 million a year ago. Net income from continuing operations for Q1 was $91.7 million, or $0.39 per share on a diluted basis, as compared to a net income of $146 million, or $0.68 per share on a diluted basis, for the first quarter of 2014.
“We delivered strong results for Radian in the first quarter, driven primarily by outstanding credit trends in our mortgage insurance business, commented Radians Chief Executive Officer S.A. Ibrahim. The last twelve months have been a turning point for Radian, as we have eliminated a significant portion of our legacy risk and therefore simplified our company with a focus on our core strengths. Today, we are better positioned to drive long-term value, both from our large and growing mortgage insurance portfolio and by broadening our future sources of revenue through our new mortgage and real estate services businesses.”
On valuation measures, Radian Group Inc. shares trade at a trailing-12 P/E of 4.38, a forward P/E of 10.66 and a P/E to growth ratio of 0.87. The median Wall Street price target on the name is $21.00 with a high target of $24.00. Currently ticker boasts 10 ‘Buy’ endorsements, compared to 2 ‘Holds’ and no ‘Sell’.
Profitability-wise, RDN has a t-12 profit and operating margin of 89.45% and 47.21%, respectively. The $3.49 billion market cap company reported $3.7 billion in cash vs. $1.21 billion in debt in its most recent quarter.
RDN currently prints a one year return of 33.36% and a year-to-date return of 9.05%.
Celgene Corporation (CELG) dropped $2.20, or 1.94%, to $111.00 in pre-market trading after it reported fiscal results for the first quarter.
In its quarterly report, the biotechnology company said it earned $1.07 per share on a non-GAAP basis, above the $1.06 per share analysts were expecting. Revenue rose 20.3% to $2.08 billion, above views for $2.1 billion.Q1 profit came in at $718.9 million, or $0.86 per share, from $279.7 million, or $0.33 per share, a year earlier.
“Our first quarter results reflect the strength of our product portfolio and we expect the multiple global regulatory approvals achieved during the quarter to drive near term growth,” said in a press release Bob Hugin, Chairman and Chief Executive Officer of Celgene Corporation. “Our continued investments in our franchises, innovative therapies and technologies position us for sustained growth beyond 2020.”
On valuation measures, Celgene Corp. shares, which currently have an average 3-month trading volume of 6.05 million shares, trade at a trailing-12 P/E of 47.36, a forward P/E of 17.97 and a P/E to growth ratio of 0.92. The median Wall Street price target on the name is $143.00 with a high target of $163.00. Currently ticker boasts 21 ‘Buy’ endorsements, compared to 4 ‘Holds’ and 1 ‘Sell’.
Profitability-wise, CELG has a t-12 profit and operating margin of 26.07% and 35.16%, respectively. The $90.63 billion market cap company reported $7.3 billion in cash vs. $6.3 billion in debt in its most recent quarter.
CELG currently prints a one year return of 54.33% and a year-to-date return of 1.20%.